Come up with a name for your new list and we'll add to it:
Syntimmune raised a round of funding on June 21, 2017. Investors include
Apple Tree Partners.
Syntimmune is advancing novel therapies based on its leading position in the biology of the neonatal Fc receptor (FcRn). FcRn is a well-validated target for IgG-mediated autoimmune diseases and repres…